Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Alcohol Use Disorder (AUD)
Interventions: Zonisamide, Placebo; Drug
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: AMG 127, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Lake Forest, California • Aventura, Florida

Conditions: Alzheimer's Disease
Interventions: CPC-201; Drug
Lead sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc; Industry
Eligibility: 50 Years to 79 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Pain, Post Operative, Quality of Life
Interventions: Ibuprofen 600 mg, Placebo, Acetaminophen; Drug
Lead sponsor: Marquette University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Healthy Volunteer
Interventions: RO6811135, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Alzheimer Disease
Interventions: NP001, Placebo; Drug
Lead sponsor: Beau Nakamoto; Other
Eligibility: 55 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Healthy Adult Subjects
Interventions: ONO-7746; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ulcerative Colitis Acute
Interventions: Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Respiratory Syncytial Virus Infections
Interventions: D46/NS2/N/ΔM2-2-HindIII, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 24 Months
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
Interventions: docetaxel, placebo, gefitinib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer's Disease
Interventions: lorazepam, placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Insulin Resistance
Interventions: BVS857, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chula Vista, California • Tacoma, Washington

Conditions: Cerebral Cavernous Malformation
Interventions: Atorvastatin, Placebo; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lupus Erythematosus, Systemic
Interventions: Placebo, MEDI-570 0.03 MG, MEDI-570 0.1 MG, MEDI-570 0.3 MG, MEDI-570 1 MG; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Long Beach, California • San Leandro, California • Fort Lauderdale, Florida + 6 more

Conditions: Acute Decompensated Heart Failure
Interventions: Experimental: Placebo, Experimental: Metolazone; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Osteoarthritis, Knee
Interventions: UBX0101, Placebo; Drug · Other
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: El Cajon, California • La Mesa, California • Miami, Florida + 4 more

Conditions: Healthy
Interventions: 50 mg AVL-292, 100 mg AVL-292, 200 mg AVL-292, 350 mg AVL-292, Placebo capsules; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: GSK3739937 (PIB), Placebo, GSK3739937 (Tablet); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: SB-756050 immediate release capsule, SB-756050 modified release capsule, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sleep Deprivation
Interventions: HBS-104, Placebo; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Healthy
Interventions: NM8074, Placebo; Drug
Lead sponsor: NovelMed Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Subjects
Interventions: MGD010, Placebo, Hepatitis A vaccine; Drug · Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy, no Evidence of Disease
Interventions: retinoid 9cUAB30, placebo, pharmacological study, laboratory biomarker analysis, cancer prevention; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers (HV)
Interventions: Investigational Drug: IBI3042, Matching Placebo; Drug
Lead sponsor: Fortvita Biologics (USA)Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lenexa, Kansas

Search by objective public record fields.

The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

Preemptive Ibuprofen Effects on Pain Perception Following Extraction and Bone Graft

A Study of Single Dose RO6811135 in Healthy Volunteers

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

ONO-7746 Study in Healthy Adult Subjects

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer

The Impact of Lorazepam on Cognition in APOE e4 Carriers

Safety and Tolerability of BVS857 in Subjects With Insulin Resistance

Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

Phase 1 Study of MGD010 in Healthy Subjects

Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers

A Study of IBI3042 in Healthy Adult Participants